Ultragenyx Pharma (NASDAQ: RARE) reported Q1 EPS of ($2.05), $0.36 worse than the analyst estimate of ($1.69). Revenue for the quarter came in at $36.31 million versus the consensus estimate of $36.58 million.

“The global coronavirus pandemic has created unprecedented challenges for the world at large, and I am proud of the company’s continued efforts to assure an uninterrupted supply of our therapies” said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx. “We delivered strong financial results in the first quarter, and our commercial business so far has been manageably impacted and resilient, though the global crisis continues. The FDA reviews for Crysvita for TIO and UX007 for LC-FAOD are on track to be completed in the coming months. Our gene therapy franchise has recently been bolstered by our recent manufacturing collaboration with Daiichi Sankyo, and our two clinical-stage gene therapy programs continue to proceed.”

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.